Natural products offer unparalleled chemical diversity and biological activity, but their complex mechanisms of action often pose significant challenges for target identification and pathway elucidation. To address these challenges, our company has established a comprehensive label-free omics-based approaches. By integrating advanced transcriptomics, proteomics, cytology, metabolomics, and bioinformatics, our platform enables systematic, unbiased, and mechanism-driven investigation of bioactive compounds. These approaches allow researchers to move beyond single-target hypotheses and instead gain a holistic understanding of biological responses at the molecular, cellular, and system levels.
What are Omics-Based Approaches?
Omics-based approaches refer to the collective characterization and quantification of pools of biological molecules that translate into the structure, function, and dynamics of an organism. In the context of drug discovery, "Omics" provides a systemic view of the cellular landscape. Unlike target-based screening, which starts with a known protein, Omics-based target ID is phenotype-driven. When a bioactive natural product is introduced to a cell, the cell reacts by modulating its gene expression, protein abundance, and metabolic flux. By capturing these "snapshots" using high-throughput technologies, we can identify which nodes in a biological network are being perturbed, leading us directly to the upstream target.
Explore Our Omics-Based Approaches Technology Platform
Our platform integrates five core pillars to provide a multi-dimensional understanding of drug-target interactions.
Transcriptomics
Transcriptomics plays a foundational role in drug target identification by revealing global gene expression changes in response to bioactive natural products. Through high-resolution RNA sequencing and differential expression analysis, we identify:
- Core genes directly or indirectly regulated by compound treatment
- Enriched signaling pathways and transcriptional networks associated with therapeutic effects
- Disease-relevant gene signatures that link compounds to known or novel targets
By comparing transcriptional profiles across conditions, doses, or reference compounds, transcriptomics enables target pathway inference and supports hypothesis-driven validation of candidate drug targets.
Proteomics
Proteomics provides a direct functional layer for drug target identification, as proteins represent the primary molecular targets of most therapeutics. Our label-free quantitative proteomics platform enables:
- Identification of differentially expressed or stabilized proteins upon compound treatment
- Detection of pathway-level protein modulation and signaling cascade alterations
- Discovery of potential direct targets and downstream effectors
In combination with bioinformatics-driven network analysis, proteomics allows us to prioritize proteins that are most likely involved in the compound's mechanism of action, supporting high-confidence target nomination.
Cytology
Cytology offers a phenotype-driven perspective on target identification by linking molecular perturbations to functional cellular outcomes. Using high-content imaging and quantitative image analysis, we assess:
- Compound-induced morphological and organelle-level changes
- Cellular responses such as apoptosis, autophagy, cell cycle arrest, or differentiation
- Phenotypic signatures that can be mapped to specific target classes or pathways
By correlating phenotypic patterns with omics-derived molecular targets, cytology serves as a critical layer for functional validation and target relevance assessment.
Metabolomics
Metabolomics captures compound-induced alterations in endogenous metabolites, offering direct insights into enzyme activity and metabolic pathway modulation. Our metabolomics platform supports:
- Identification of metabolic pathways affected by bioactive compounds
- Inference of enzyme targets based on substrate–product imbalances
- Discovery of metabolic biomarkers linked to target engagement
This approach is particularly powerful for identifying metabolic enzymes, transporters, and energy-related targets, which are often underrepresented in traditional target discovery strategies.
Bioinformatics
Bioinformatics is the integrative engine that transforms multi-omics data into actionable drug target insights. By combining transcriptomic, proteomic, cytological, and metabolomic datasets, we perform:
- Cross-omics target convergence and validation
- Network-based target prioritization and pathway reconstruction
- Mechanism-of-action modeling and target ranking
Our bioinformatics-driven integration ensures that identified targets are not only statistically significant but also biologically meaningful and pharmacologically relevant, greatly improving the success rate of downstream drug development.
Instruments and Equipment at Our Platform
To ensure data accuracy, sensitivity, and reproducibility, our platform is equipped with state-of-the-art instrumentation, including:
- High-throughput next-generation sequencing (NGS) systems
- High-resolution LC-MS/MS systems for proteomics and metabolomics
- Automated sample preparation and liquid handling platforms
- High-content imaging systems for cytological profiling
- High-performance computing infrastructure for bioinformatics analysis
- …
All instruments are operated under strict quality control standards to support research-grade and preclinical-level studies.
Our Advantages
- True Label-Free Environment: We eliminate the risk of "false negatives" caused by bulky chemical tags, ensuring the natural product behaves exactly as it would in a biological system.
- High-Resolution Multi-Omics Integration: We don't just provide one type of data. Our platform integrates transcriptomic and proteomic data to cross-validate findings, significantly reducing the "false discovery rate."
- Deep Expertise in Natural Products: We understand the unique challenges of natural products, such as low solubility, complex scaffolds, and multi-target profiles.
- End-to-End Service: From the initial treatment of cell lines to the final bioinformatic report identifying the top 3-5 high-confidence targets, we manage the entire pipeline.
- Speed and Scalability: Our automated workflows allow us to process complex natural product libraries in a fraction of the time required by traditional biochemical assays.
Omics-based approaches provide a powerful, unbiased, and label-free solution to one of the most challenging aspects of bioactive natural product drug discovery—accurate target identification. By leveraging omics-based approaches, our company empowers researchers to unlock the full therapeutic potential of bioactive natural products through robust, label-free, and system-level target identification technologies.
Online Inquiry
Frequently Asked Questions (FAQ)
Q1: Why are omics-based approaches suitable for natural product research?
Q2: Are your technologies applicable to both pure compounds and extracts?
A: Yes. Our platform is optimized for purified monomers, fractions, and complex natural extracts.
Q3: Do you provide customized study designs?
A: Yes. All projects are tailored to the specific scientific questions and characteristics of the bioactive compounds.